Leukemia Adapted Protocol

Participants:

• All patients with have de novo AML presenting to Kamuzu Central Hospital (KCH) in Lilongwe, Malawi will be offered enrollment into the study.
• Patients must be <18 years of age at time of study enrollment.
• Patients must begin treatment according to the 2023 KCH AML therapy CPG.
• All patients at the treating center receiving curative-intent therapy for AML are treated on the 2023 KCH AML standard of care CPG based on the SIOP AML guidelines, independent of participation in research.
• Patients should ideally be consented for data collection within one week of confirmatory diagnosis to ensure highest quality of prospective data collection.

The therapy guideline used at KCH is based upon the published international guidelines for treating pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care at KCH.

Data Collection Schedule:

All study measurements in this study are routinely captured as part of clinical care. No additional clinical studies will be obtained from patients as a consequence of enrollment onto the LEAP study.

• On-treatment schedule Patients are routinely admitted inpatient to the pediatric cancer unit at the start of each chemotherapy cycle. Patients remain inpatient according to standard practices of the unit until they no longer require routine blood product transfusions and their absolute neutrophil count is rising. Patients are discharged home for ~1 week prior to returning to start the subsequent cycle, but generally no later than 2 weeks from discharge.

Required Data Items are all routinely obtained as part of standard of care:

• Bone marrow aspirate with morphology +/- trephine biopsy
• Bone marrow flow cytometry OR immunohistochemistry
• Lumbar puncture with cerebrospinal fluid cell count & morphological evaluation
• Leukemia cytogenetics
• Lanksy score
• Weight, height, MUAC
• History & physical
• Complete blood count
• Serum electrolytes
• Confirmation of HIV serostatus (standard of care for all pediatric patients in Malawi)
• Chest X-ray
• Echocardiogram
• Adverse event monitoring
• PROMIS-25 parent & patient questionnaire (additional research-only evaluation)
• REDCap data upload
• Post-treatment schedule Patients will be followed up by telephone monthly for the first six months off therapy. In-person visits routinely occur at 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months following completion of therapy. They are followed annually thereafter.

Required Data Items:

• History and confirmation of vital status
• Physical exam
• Complete/full blood count
• PROMIS-25 questionnaire
• REDCap data upload

Statistical analysis:

Sample size determination of this study is based on accrual capacity of the study site, not from statistical power. Based on diagnoses over the previous three years at Kamuzu Central Hospital in Malawi, the investigators expect at least 10 de novo cases/year of AML.

Primary Endpoint

CPG Implementation Success will be a composite endpoint comprised of:

• Feasibility: proportion of patients completing the CPG
• Effectiveness: proportion of patients in complete remission (CR) by the end of Induction

Implementation will be deemed successful if 1) ≥50% of patients are able to complete the CPG; AND 2) The historical benchmark of end-of-induction complete remission (CR) of 40% is maintained.

Rates of CR (effectiveness outcome) and CPG completion (implementation outcome) will be monitored continuously by the study statistician team using an adaptation of the method of Ivanova and colleagues. This method provides a Pocock-type boundary so that the probability of crossing the boundary is at most 5% when the true rate of the event crosses the acceptable threshold. For the effectiveness threshold of CR, we will use the established historical rate of CR of 40% achieved on the old standard of care for AML in Malawi. The probability of boundary crossing rises to 24%, 68%, and 98% if the CR rate drops to 30%, 20%, and 10%, respectively, with corresponding accruals of N=28, 22, and 14. Similarly, for rate of CPG completion, we will use a threshold of 50%. The probability of boundary crossing rises to 22%, 59%, and 92% if the rate of completion rate drops to 40%, 30%, and 20%, respectively, with corresponding expected accruals of N=27, 22, and 15.

Criteria for completing the CPG are:

• Completing all required chemotherapy cycles (Induction 1, Induction 2, Consolidation 1, Consolidation 2) and achieving transfusion independence following Consolidation 2 outside of the setting of relapse or bone marrow failure (in which case therapy will be considered complete for the purposes of the study outcome). Note that pre-phase is not required for completion.
• Completion of Inductions 1 and 2 but not in CR at the end of Induction.
• Completion of Inductions 1 and 2 having achieved CR by the end of Induction 2 but having had relapse prior to completing Consolidation 2.
• All patients with early mortality (≤42 days), treatment-related mortality, or treatment abandonment of curative-intent therapy will be considered incomplete.
• Patients removed from curative-intent therapy due to toxicity will be considered incomplete.

Complete Remission is defined as <5% myeloblasts on bone marrow evaluation.

Secondary Endpoints

• Event-free, relapse-free, and overall survival at 12 & 24 months from diagnosis
• Proportion of patients with CTCAE ≥3 adverse events
• Patient-reported outcomes at diagnosis, end of induction, end of therapy, and 6 months post-therapy.
• Cytogenetic characteristics of myeloblasts
• Proportion of discrete treatment and supportive care CPG elements received/completed as prescribed

Inclusion criteria

• Age Patients must be <18 years of age at time of study enrollment.
• Diagnosis

Patients must be diagnosed with de novo AML according to 2022 WHO 5th Edition classification with or without extramedullary disease. Patients must have one of the following:

• Bone marrow myeloblasts ≥20%. In cases of dry taps due to fibrosis, myeloblast percentage can be estimated from a bone marrow biopsy core specimen. Due to unavailable molecular/cytogenetic diagnostics in Malawi, patients with <20% bone marrow myeloblasts can be included in the study at the discretion of the treating oncologist with rationale documented.
• In cases where a bone marrow evaluation is not safe/feasible, a peripheral blood sample may be used with a documented absolute myeloblast percentage of ≥1000/μL calculated based on a total white blood cell count and percentage circulating blasts.
• Therapy Patients must begin treatment according to the 2023 KCH AML therapy CPG.

Exclusion criteria

• Patients with any of the following conditions or criteria will be excluded from the study:

• Juvenile myelomonocytic leukemia
• Transient myeloproliferative disorder
• Acute promyelocytic leukemia
• Mixed phenotype acute leukemia
• Trisomy 21
• Current pregnancy
• Previous or concurrent malignancy
• Isolated myeloid sarcoma
• Patients previously treated with antineoplastic therapy with the following exceptions:

• Hydroxyurea
• Corticosteroids
• Intrathecal chemotherapy at diagnosis